Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.67 |
| ▸ | PI4KA | P42356 | 2/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25404491 | 0.92 | ADORA3 (0.67) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL24371814 | 0.91 | ADORA3 (0.71) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL26598553 | 0.90 | ADORA1 (0.65) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL887801 | 0.89 | MEN1 (0.53) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL25936 | 0.88 | ADORA3 (0.75) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL24538798 | 0.88 | ADORA3 (0.75) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL23050294 | 0.88 | ADORA3 (0.75) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL12031327 | 0.88 | ADORA3 (0.75) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL25937 | 0.88 | ADORA3 (0.75) | ADORA3ADORA1DOT1LPI4KAPI4K2B | |
| SCHEMBL2550330 | 0.88 | ADORA3 (0.75) | ADORA3ADORA1DOT1LPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-03 | — | — | US | claimed |
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2024-10-10 | — | — | US | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| EP-3765476-B1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-12428441-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-20 | — | — | US | disclosed |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12077757-B2 | Modified oligonucleotides and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| CN-118345072-A | Synthetic guide molecules, compositions, and methods related thereto | 爱迪塔斯医药公司 | 2024-07-16 | — | — | CN | disclosed |
| US-6762169-B1 | IMPROVED TRANSMEMBRANE DELIVERY OF NUCLEOSIDES CONJUGATED TO AN ARYLPROPIONIC ACID LIGAND (IBUPROFEN) WHICH HAS AFFINITY FOR PLASMA PROTEIN ALBUMIN; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6656730-B1 | Attached to an arylpropionic acid that interacts with human serum albumin; acid is ibuprofen, suprofen, ketoprofen, (S)-(+)- pranoprofen, or carprofen. | ISIS PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| US-6639062-B2 | Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1185305-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1019539-A1 | COMBINATORIAL ANTISENSE LIBRARY | Oasis Biosciences, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999018238-A1 | COMBINATORIAL ANTISENSE LIBRARY | OASIS BIOSCIENCES, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | ADORA3 4551/4885ADORA1 4273/4885DOT1L 2078/4885 |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CPS1, CTPS1, CTPS2 | ADORA3 4551/4885ADORA1 4273/4885DOT1L 2078/4885 |
| US-12077757-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | ADORA3 897/4885ADORA1 2071/4885DOT1L 1115/4885 |
| US-12428441-B2 | Modified nucleoside phosphoramidites | MTAP, PNP, NT5C3B | ADORA3 297/4885ADORA1 555/4885DOT1L 2952/4885 |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, RNASEH1, HNRNPF | ADORA3 1085/4885ADORA1 1640/4885DOT1L 3863/4885 |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | NSUN2, ADAR, POLM | ADORA3 985/4885ADORA1 2193/4885DOT1L 1201/4885 |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | MTAP, PNP, NT5C3B | ADORA3 297/4885ADORA1 555/4885DOT1L 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.